India, 11th August 2025: Eyestem Research Pvt Ltd has raised funds in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE™.

The capital will enable completion of the ongoing Phase 2 clinical trial in India and support preparations for filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA).

“Strong participation by internal investors and addition of a strategic investor, underline the shared belief in Eyestem’s long-term vision of creating an innovative cell therapy platform providing scalable solutions for incurable diseases worldwide. This  $10 million fundraise will support the next leg of development and strengthen the foundation for global expansion. We continue to prioritize rigorous clinical progress and the capabilities needed to ensure global patient access to this therapy,” said Dr. Jogin Desai, Founder and CEO, Eyestem.

(L to R) Dr Jogin Desai, Dr Rajani Battu & Dr Rajarshi Pal

Continue reading Eyestem Raises Funds to Advance Eyecyte-RPE™ Through Phase 2 Clinical Trial and Towards US IND →